SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 30, 2003
Nektar Therapeutics
(Exact name of registrant as specified in its charter)
|
Delaware |
||
|
(State or other jurisdiction of incorporation) |
||
|
|
|
|
|
000-23556 |
|
94-3134940 |
|
(Commission File No.) |
|
(IRS Employer Identification No.) |
|
|
||
|
150 Industrial Road |
||
|
(Address of principal executive offices and zip code) |
||
|
|
||
|
Registrant’s telephone number, including area code: (650) 631-3100 |
||
Item 5. Other Events
On July 30, 2003, Nektar Therapeutics announced that the initial purchasers have exercised their option granted pursuant to a purchase agreement dated June 25, 2003 with respect to Nektar’s 3% convertible subordinated notes due 2010 to purchase an additional $10 million in aggregate principal amount of such notes. The closing of the additional purchase pursuant to the option increases the aggregate principal amount of 3% convertible subordinated notes sold to $110 million.
Nektar’s press release, dated July 30, 2003, titled “Nektar Announces Exercise of Option to Purchase $10 Million of Convertible Subordinated Notes” is attached hereto as Exhibit 99.1.
Item 7. Financial Statements and Exhibits
(c) Exhibits
|
Exhibit |
|
Description |
|
99.1 |
|
Press Release titled “Nektar Announces Exercise of Option to Purchase $10 Million of Convertible Subordinated Notes” dated July 30, 2003. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
NEKTAR THERAPEUTICS |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
Dated: |
July 30, 2003 |
By: |
/s/ Ajay Bansal |
|
|
|
|
|
Ajay Bansal |
|
|
|
|
|
|
|
|
|
|
|
Chief Financial Officer and Vice |
|
|
|
|
|
President, Finance and Administration |
|
3